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NOTCH1 mutations identify a genetic subgroup of chronic
lymphocytic leukemia patients with high risk of transformation
and poor outcome
N Villamor1,10, L Conde1,10, A Martı´nez-Trillos1, M Cazorla1, A Navarro1, S Bea`1, C Lo´pez1, D Colomer1, M Pinyol2, M Aymerich1,
M Rozman1, P Abrisqueta3,11, T Baumann3, J Delgado3, E Gine´3, M Gonza´lez-Dı´az4, JM Herna´ndez4, E Colado5, AR Payer5, C Rayon5,
B Navarro6, M Jose´ Terol6, F Bosch3,11, V Quesada7, XS Puente7, C Lo´pez-Otı´n7, P Jares1, A Pereira8, E Campo1,9,12 and
A Lo´pez-Guillermo3,12
NOTCH1 has been found recurrently mutated in a subset of patients with chronic lymphocytic leukemia (CLL). To analyze biological
features and clinical impact of NOTCH1 mutations in CLL, we sequenced this gene in 565 patients. NOTCH1 mutations, found in 63
patients (11%), were associated with unmutated IGHV, high expression of CD38 and ZAP-70, trisomy 12, advanced stage and
elevated lactate dehydrogenase. Sequential analysis in 200 patients demonstrated acquisition of mutation in one case (0.5%) and
disappearance after treatment in two. Binet A and B patients with NOTCH1-mutated had a shorter time to treatment. NOTCH1-
mutated patients were more frequently refractory to therapy and showed shorter progression-free and overall survival after
complete remission. Overall survival was shorter in NOTCH1-mutated patients, although not independently from IGHV. NOTCH1
mutation increased the risk of transformation to diffuse large B-cell lymphoma independently from IGHV, with this being validated
in resampling tests of replicability. In summary, NOTCH1 mutational status, that was rarely acquired during the course of the
disease, identify a genetic subgroup with high risk of transformation and poor outcome. This recently identiﬁed genetic subgroup
of CLL patients deserves prospective studies to deﬁne their best management.
Leukemia (2013) 27, 1100–1106; doi:10.1038/leu.2012.357
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is characterized by the
proliferation and progressive accumulation of mature clonal B
lymphocytes in bone marrow, blood and lymphoid tissues. The
clinical course of the disease is highly heterogeneous, with
patients requiring early treatment for disease progression and
others who have an indolent course that does not affect their life
expectancy.1,2 Several characteristics of the disease including the
IGHV mutational status, cytogenetics, the expression of several
proteins in the leukemic lymphocytes and the response to
treatment have been related to the outcome of patients.3
Whole-genome and exome sequencing have started to reveal
the complex landscape of somatic mutations in CLL with the
identiﬁcation up to now of around 80 recurrently mutated genes
with predicted functional impact.4–6 The distribution of these
mutations in different clinical and biological subgroups of patients
suggests that they may be relevant in determining the
heterogeneous behavior of the disease. However, the clinical
impact of these mutations and their stability during the course of
the disease is not well known. Activating mutations of NOTCH1
have emerged as one of the most frequent somatic aberrations in
CLL affecting up to 10–15% of patients.4,6–9 Virtually all these
mutations generate a truncated protein lacking the C-terminal
domain, that is more stable and activates the NOTCH1 signaling
pathway.4 The presence of NOTCH1 mutations in CLL cells seems
to be associated with adverse prognosis features and to confer an
adverse prognosis.4,6,8,9
In this study, we have investigated the presence of NOTCH1
mutations in a large series of CLL cases to better deﬁne their
stability along the evolution of the disease, as well as their
relationship with other clinical and biological features of
the disease and their clinical impact, particularly their inﬂuence
in the requirement of and response to therapy and the
transformation to diffuse large B-cell lymphoma (DLBCL).
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METHODS
Patients
A total of 565 patients diagnosed with CLL according to the World Health
Organization criteria10 with available DNA from samples before treatment,
containing more than 30% of tumor cells, were included in the study.
Clinical and biological data at diagnosis, treatment and follow-up were
recorded and analyzed. Patients were predominantly males (59%) with a
median age at diagnosis of 61 years and most of them in Binet stage A
(81%). The distribution of prognostic factors with adverse impact on the
evolution of patients was: unmutated IGHV in 46% of the patients
analyzed, adverse cytogenetics (del(11)(q22.3) and del(17)(p13.1)) in 14%,
high expression of CD38 or ZAP-70 in leukemic lymphocytes in 33% and
34% of patients, respectively. After a median follow-up of 6.2 years (range
0.2–27) for surviving patients, 259 patients remained untreated. The
remainder received different therapies along the years, including
chlorambucil (n¼ 105), monotherapy with purine analogs (n¼ 36),
ﬂudarabine-based polychemotherapy without rituximab (n¼ 51),
ﬂudarabine-based polychemotherapy with rituximab (n¼ 68), CHOP-like
regimens (n¼ 26) and other therapies (n¼ 20). Actuarial median time to
treatment (TTT) was 5.3 years. Response to treatment was evaluated
according to the International Workshop on Chronic Lymphocytic
Leukemia criteria.11 In patients achieving a complete response (CR),
minimal residual disease (MRD) was evaluated by sensitive multiparametric
ﬂow cytometry (0.01%),12,13 according to the International Workshop on
Chronic Lymphocytic Leukemia recommendations.11 CR patients in whom
no study of MRD was performed were considered as CR MRD-positive in all
the analyses. Transformation to DLBCL was diagnosed by cytology in
2 cases and histology in 34 cases. In all, 204 patients died during the
follow-up, with a median overall survival (OS) of 12 years.
Informed consent to participate in the study was obtained according to
the guidelines of the local Ethic Committees.
Gene ampliﬁcation and sequencing
DNA and RNA were extracted from mononuclear cells containing more
than 30% of tumor cells. The median percent of tumor cells in the samples
was 90% (range: 30–100%), with only 24 samples (4%) having less than
50% of CLL cells. PCR for IGHV was carried out according to ERIC
guidelines.14,15 IGHV sequences were aligned using Immunoglobulin
database (http://www.imgt.org).
Exon 34 of NOTCH1 was ampliﬁed with forward: 50-ATGGCTACCTGTCA
GACGTG-30/ reverse: 50-TCTCCTGGGGCAGAATAGTG-30 and forward: 50-G
AGCTTCCTGAGTGGAGAGC-30/ reverse: 50-CCTGGCTCTCAGAACTTGCT-30 pri-
mers. These ampliﬁcations cover the whole PEST domain and most of the
TADD domain and include 97% of NOTCH1mutations previously described in
CLL. The sensitivity of the Sanger technique employed for assessment of the
allelic representation of NOTCH1 mutational status was 10% (equivalent to
20% tumor cells carrying the mutations in heterozygosis in all tumor cells), as
assessed by DNA titration experiments (n¼ 2) by diluting genomic DNA from
a heterozygous mutated sample with 99% of tumor cells into normal DNA
simulating 50–10% of tumor cells. In these two cases, the allelic
representation of NOTCH1 mutations was around 50% as assessed by next-
generation sequencing technologies. A clonospeciﬁc PCR with a sensitivity of
3% of allelic representation was performed in cases that showed changes in
NOTCH1 mutational status (see Supplementary Material and Supplementary
Table 1). Exon 5 of MYD88 and exons 14, 15, 16 and 18 of SF3B1 were
sequenced as previously described.4,5 Exons 4 – 9 of TP53 were ampliﬁed as
previously described by International Agency for Research on Cancer (IARC)
Consortium (http://www-p53.iarc.fr). PCR products were puriﬁed and
sequenced as previously described.5
Statistical analysis
Fisher’s test or non-parametric tests were employed to correlate clinical
and biological variables according to NOTCH1 mutational status. The main
endpoints were OS, relative survival (adjusted for expected survival in the
general population), TTT, progression-free survival (PFS) from CR achieve-
ment (considering need of more treatment, transformation to DLBCL or
death, whichever occurred ﬁrst, as events), and incidence of transforma-
tion to DLBCL. Survival curves were plotted by the Kaplan and Meier
method and compared by the log-rank test. The independent value of
NOTCH1 mutations to predict the various time-to-event outcomes was
assessed by multivariate Cox regression analysis. Relative survival was
calculated by the cohort method described by Dickman et al.16 Estimates
of expected survival were calculated by the Ederer II method17 from
Spanish life tables stratiﬁed by age, sex and calendar year that were
obtained from the Human Mortality Database (http://www.mortality.org).
The impact of NOTCH1 on the risk of transformation to DLBCL was
evaluated by two different methods. First, a nested case–control study in
which 2–4 randomly selected control patients were matched to each case
patient by the IGHV mutational status and the duration of follow-up, to
guarantee that controls have had the same opportunity as cases with
transformation to DLBCL. The association between the NOTCH1 status and the
risk of transformation to DLBCL was then assessed by logistic regression,
conditional on the set of matched cases and controls. Second, we analyzed
the inﬂuence of NOTCH1 on the cumulative incidence of transformation to
DLBCL by taking death as a competing risk. The multivariate adjustment for
other factors predicting the transformation to DLBCL was performed within
the framework of competing risks by the method of Fine and Gray.18 The
replicability of the nested case–control study and the competing-risks model
were assessed by bootstrap resampling. For this purpose, control case
selection for nested case–control analysis of DLBCL transformation was done
by constraining the matching criteria of dates of diagnosis and last follow-up
of the controls for a given case that anteceded the diagnosis of CLL and
postdated DLBCL transformation, respectively, of that given case. The
replicability of the nested case–control study and the competing-risks model
analyzing the effect of NOTCH1 on the risk of DLBCL transformation were
assessed by bootstrap resampling. A total of 1000 samples, the same size as
the original series, were built through random extraction with reposition, so
that in each sample a given patient may either not be represented at all or
represented once, twice or more times. The parameters assessed by
resampling were the P-values of either the subhazard ratios of the Fine and
Gray’s regression or the odds ratios of the conditional logistic regression.
Bootstrap resampling allows verifying that the predictive value of NOTCH1
status was not critically dependent on the particular composition of the
present series.
All statistical tests were two-sided and the level of statistical signiﬁcance
was 0.05. All the analyses were conducted with the use of the Stata 11
software (http://www.stata.com) and the SPSS 19 software (http://
www.ibm.com). For relative survival analysis, the Stata routines developed
by Paul Dickman (Karolinska Institutet, Stockholm, Sweden; available at
http://www.pauldickman.com) were used.
RESULTS
Frequency of NOTCH1 mutations and sequential analysis
Of the 565 patients, 63 (11%) carried somatic mutations of
NOTCH1. Of them, 54 (86%) had the dinucleotide deletion
p.P2514Rfs*4, 3 patients had a p.L2482Ffs*2, 2 patients had a
p.Q2394* and 1 patient each p.Q2444*, p.Q2404*, p.Q2503* and
p.P2437fs*36.
To determine the stability of the NOTCH1 mutational status
during the clinical evolution of the CLL, we assessed NOTCH1
mutations in two sequential samples of 200 patients with a
median interval of 3.5 years (0.2–21.6 years). The disease status at
the time of both samples, interval between samples and changes
in NOTCH1 are described in Table 1. A change in NOTCH1 was
observed in 3 of 200 patients (1.5%). Two patients with
p.P2514fs*4 at diagnosis had a wild-type NOTCH1 4 and 7 years
later after having received two lines of treatment (chlorambucil
and ﬂudarabine-containing therapy in one, CHOP-like chemother-
apy and an autologous stem cell transplantation in the other).
Another patient with unmutated NOTCH1 at diagnosis acquired a
NOTCH1 mutation (p.Q2501fs*6) after 9.5 years of stable disease.
In summary, only 0.5% of patients acquired a mutation in NOTCH1
during the follow-up, suggesting that in most patients the status
of NOTCH1 is stable throughout the course of the disease. To
better assess the changes in NOTCH1 mutational status, a more
sensitive clonospeciﬁc PCR was used. Cells carrying NOTCH1
mutation were detected in samples from these three patients that
were negative by Sanger.
NOTCH1 mutations are associated with adverse biological and
clinical features
The main biological features of the patients according to the
NOTCH1 mutational status are listed in Table 2. NOTCH1-mutated
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CLL patients showed more frequently unmutated IGHV, as well as
elevated expression of CD38 and ZAP-70. In addition, they had
more frequently trisomy 12, and less frequently del(13q)(q14.3)
than cases with NOTCH1-unmutated. No case carried simultaneous
mutation of NOTCH1 and MYD88.
NOTCH1-mutated patients had more frequently advanced Binet
and Rai stages, elevated serum lactate dehydrogenase and
elevated beta-2-microglobulin than unmutated patients (Table 3).
TTT, response and outcome according to NOTCH1 mutational
status
A total of 259 patients have not required therapy during the
follow-up. This proportion was lower in patients with NOTCH1-
mutated than in NOTCH1-unmutated cases (Table 3). Patients in
Binet stage A and B with NOTCH1-mutated showed shorter TTT
than NOTCH1-unmutated patients (median TTT 1.8 vs 6.0 years;
Po0.001) (Figure 1). Of note, 17 of 63 (27%) NOTCH1-mutated
patients have never received treatment after a median follow-up
of 2.5 years (range: 0.6–16.5 years). The multivariate analysis of
TTT, including Binet stage (A vs B), NOTCH1 and IGHV mutational
status, showed that only Binet stage and IGHV mutational status
were independent in predicting need of treatment.
The status of NOTCH1 was similar among groups of patients
receiving different types of treatment. The response to therapy is
listed in Table 3. Refractoriness to treatment was signiﬁcantly
more frequent among NOTCH1-mutated than in unmutated
patients. Moreover, MRD-negative CR rates were lower in
NOTCH1-mutated patients.
In all, 54 of the 115 patients achieving a CR eventually required
further treatment, and 6 died without further therapy. PFS from CR
achievement was shorter in NOTCH1-mutated than in unmutated
patients (Table 3, Figure 2a). Unmutated IGHV and MRD-positive
CR also predicted shorter PFS from CR. In a multivariate analysis,
the three variables, namely NOTCH1-mutated (P¼ 0.02; hazard
ratio (HR)¼ 2.4), IGHV unmutated (P¼ 0.001, HR¼ 4.0) and
MRD-positive CR (P¼ 0.003, HR¼ 2.6) maintained independent
value to predict failure, in the Cox model with 105 patients. In
addition, the survival from CR achievement was signiﬁcantly
shorter in NOTCH1-mutated patients (median survival from CR: 4.9
vs 8.7 years, respectively; P¼ 0.003; Figure 2b). The prognostic
value for OS from CR was not independent from IGHV and MRD
status. Similar results were observed when the analysis
was restricted to patients treated with ﬂudarabine-containing
regimens (data not shown).
After a median follow-up of 6.2 years, 204 patients have died.
The main variables associated with poor OS were advanced
clinical stage, unmutated IGHV, high expression of CD38 and ZAP-
70, adverse cytogenetics, elevated serum lactate dehydrogenase,
high beta-2-microglobulin and short lymphocyte-doubling time
(Po0.001 in all comparisons). Patients with NOTCH1-mutated CLL
showed shorter OS when compared with unmutated patients (10-
year OS: 35% vs 64%; Po0.001) (Table 3, Figure 3). NOTCH1
p2514fs*4 mutation and the other NOTCH1 mutations had similar
impact on OS (Supplementary Figure 1). Multivariate analysis
identiﬁed, in a model with 404 cases, the following unfavorable
variables to predict OS: age (HR¼ 1.04; Po0.001), advanced Binet
stage (HR¼ 1.7; P¼ 0.002), high beta-2-microglobulin (HR¼ 2.2;
Po0.001) and unmutated IGHV (HR¼ 4.2; Po0.001). NOTCH1
mutations did not reach independent prognostic value for OS.
To analyze the impact of NOTCH1 mutations on the life
expectancy of CLL patients, relative OS adjusted by general
population mortality rates was calculated. As shown in Figure 4,
the life expectancy of patients with NOTCH1-mutated CLL was
signiﬁcantly lower than that of the general population being
around 50% after 10 years.
Table 2. Main biological features of 565 patients with CLL according to the NOTCH1 mutational status
Parameter Category NOTCH1 unmutated (n¼ 502) NOTCH1 mutated (n¼ 63) P
IGHV Unmutated 173/416 (42%) 44/53 (83%) o0.001
CD38 High 127/441 (29%) 37/52 (71%) o0.001
ZAP-70 High 125/414 (30%) 34/48 (71%) o0.001
Del(13q)(q14.3) 179/385 (46%) 14/47 (30%) 0.03
Genetics Del(11q)(q22.3) 36/339 (11%) 6/43 (14%) n.s.
Trisomy 12 50/344 (14%) 15/44 (34%) 0.002
Del(17p)(p13.1) 11/340 (3%) 2/43 (5%) n.s.
SF3B1 Mutated 32/332 (10%) 5/39 (13%) n.s.
MYD88 Mutated 11/367 (3%) 0/48 (0%) n.s.
Abbreviations: CLL, chronic lymphocytic leukemia; n.s., not significant. CD38 high: 430% of positive CLL cells; ZAP-70 high:X20% of positive CLL cells; IGHV
unmutated:X98% homology with germline.
Table 1. Sequential analysis of NOTCH1 mutations in patients with CLL
First sample Second sample N NOTCH1 mut/unmut Intervala (years) Changes Type of change
Stable 91 7/84 3.4 (0.5–19) 1 Unmut--4mut
Diagnosis/stable Progression 44 6/38 2.0 (0.7–22) 0
Post-treatment 42 12/30 5.2 (0.6–17) 2 Mut--4unmut
Mut--4unmut
Progression Post-treatment 6 0/6 4.6 (2.5–9)
Post-treatmentb Post-treatment 17 3/14 4.2 (0.2–13) 0
Total 200 28/172 3.5 (0.2–21.6) 3/200 (1.5%)
Abbreviations: CLL, chronic lymphocytic leukemia; mut, mutated; unmut, unmutated. The percent of CLL cells (mean and s.d.) in the first and second sample
were 83±15% and 92±12%, respectively. aInterval expressed as median and range in parenthesis. bThe 17 patients with both samples after treatment were
only collected for the sequential analysis of NOTCH1 configuration.
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NOTCH1 mutations increase the risk of transformation to DLBCL
A total of 36 patients developed transformation to DLBCL. At
10 years from diagnosis, when 143 patients were still at risk, the
cumulative incidences of transformation or death without
transformation were 8% and 33%, respectively. The inﬂuence of
NOTCH1 mutations on the incidence of transformation to DLBCL
was investigated after adjustment for other variables associated
with transformation, including high expression of CD38, trisomy
12, absence of del(13q), previous exposure to purine nucleoside
analogs or anthracyclines and unmutated IGHV. Only NOTCH1-
mutated (HR¼ 5.2; Po0.001) and IGHV-unmutated (HR¼ 3.6;
P¼ 0.006) were independently associated with a higher risk
of DLBCL (n¼ 469). At the resampling test of replicability,
NOTCH1-mutated was selected as an independent predictor of
transformation to DLBCL in 63% of the 1000 bootstrap samples,
whereas unmutated IGHV was selected in 13%. Figure 5 shows the
cumulative incidence of transformation to DLBCL according to
NOTCH1 status. At 10 years from diagnosis, the cumulative
incidence of transformation was 6% and 31% for NOTCH1-
unmutated and NOTCH1-mutated patients, respectively.
The case–control study included the 36 case patients who
evolved into DLBCL and 168 who did not and were matched to
the cases by the IGHV mutational status and length of follow-up.
Median follow-up to diagnosis of DLBCL in case patients or to
death or last follow-up in control patients was 4.5 years (range,
0.02–23) and 9.8 years (range, 0.4-39), respectively. At the
conditional logistic regression, harboring NOTCH1 mutations was
strongly associated with progression to DLBCL (HR: 8.0, %
CI: 3.2–20, Po0.001). At the resampling test of replicability, the
association between mutated NOTCH1 and progression to DLBCL
was statistically signiﬁcant in 79% of the 1000 bootstrap samples.
In 15 patients, NOTCH1 and TP53 were analyzed at transforma-
tion: 6 cases had mutation in NOTCH1 (40%), 2 in TP53, 5 in both
genes and 2 had no mutations. In 8 cases, the status of NOTCH1 was
available in samples before transformation and it was identical than
at transformation (5 unmutated and 3 mutated). Regarding TP53,
two patients of eight analyzed acquired the mutation at
transformation (both being NOTCH1-mutated). In addition, at time
of transformation simultaneous samples of DLBCL and non-
transformed peripheral blood CLL were available in six patients.
In all cases, NOTCH1 conﬁguration was identical in both samples
(four NOTCH1-mutated and two NOTCH1-unmutated).
DISCUSSION
The use of whole-genome and exome sequencing has revealed
the presence of recurrent somatic mutations in CLL with speciﬁc
Table 3. Main clinical characteristics and outcome of the 565 patients with CLL according to the NOTCH1 mutation
Parameter Category NOTCH1 unmutated (n¼ 502) NOTCH1 mutated (n¼ 63) P
Gender Male (%) 299 (60%) 37 (59%) n.s.
Age (years), median (range) 61 (24–93) 63 (43–94) n.s.
Binet stage A 414 (83%) 40 (65%)
B 65 (13%) 19 (31%) 0.001
C 22 (4%) 3 (5%)
0 285 (57%) 27 (44%)
Rai stage I–II 189 (38%) 27 (44%) 0.03
III–IV 27 (6%) 8 (13%)
Lymphocytes ( 109/l), median (range)a 12.7 (1.1–233) 11.4 (1.7–339) n.s.
Hemoglobin (g/l), median (range) 139 (45–175) 136 (63–177) n.s.
Platelets (x109/l), median (range) 195 (19–470) 196 (92–433) n.s.
LDH 4UNL 44/468 (9%) 12/59 (19%) 0.02
Beta-2-microglobulin 4UNL 170/421 (40%) 32/56 (57%) 0.02
LDT o 1 year 65/361 (18%) 11/41 (27%) n.s.
Never-treated patients 242/502 (48%) 17/63 (27%) 0.002
Response to first-line treatmentb MRDnegc 51/225 (23%) 4/45 (9%) 0.04
CR 59/225 (22%) 11/45 (24%)
PR 98/225 (44%) 19/45 (42%)
Failure 27/225 (12%) 11/45 (24%) 0.03
10-year TTT (95% CI) Binet stage A and B 59% (54–64) 88% (77–99) o0.001
Median PFS from CR (years) CR 4.8 2.0 o0.001
10-year DLBCL (95% CI) All 6% (3–9) 41% (21–61) o0.001
10-year OS (95% CI) All 64% (59–69) 35% (20–50) o0.001
Abbreviations: CLL, chronic lymphocytic leukemia; CR, complete response MRD positive or MRD not assessed; DLBCL: transformation to diffuse large B-cell
lymphoma; LDH, lactate dehydrogenase; LDT, lymphocyte-doubling time; MRDneg, complete response with negative minimal residual disease (MRD) status;
n.s., not significant; OS overall survival; PFS, progression-free survival; PR, partial response; TTT, time to treatment; UNL, upper normal level; 95% CI, 95%
interval of confidence aOf the 565 patients, 70 (12.4%) were diagnosed as small lymphocytic lymphoma. bIn 36 patients, response was not assessable (35
NOTCH1 unmutated, 1 NOTCH1-mutated. cPatients in whom MRD was not available were considered as CR.
Figure 1. TTT in Binet stage A and B CLL patients according to
NOTCH1-mutated (solid line) and NOTCH1-unmutated (dashed line)
(Po0  001). The 95% confidence interval for each group of patients
is depicted.
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gene mutations clustering in one of the two major subgroups of
CLL according to the IGHV mutational status.4,5,19,20 Among the
most frequently mutated genes, we and others have found
NOTCH1 and SF3B1 mutations in up to 10–15% of CLL samples.
Preliminary data suggested an unfavorable prognostic impact of
NOTCH1 mutation.4,6,8,9,20 Thus, to gain insight into the impact
of NOTCH1 mutations in CLL, we have extended our initial series
and we have analyzed in depth the role of NOTCH1 mutation in
the outcome of CLL patients with particular emphasis in the
evaluation of the response to treatment and transformation to
DLBCL.
Whether NOTCH1 mutational status remains stable or, on the
contrary, it changes over time in the evolution of the disease is an
important issue not well established at present. There is evidence
that patients at progression and relapse have more frequently
NOTCH1 mutations,6,8,20 as we also observed in our series
(Table 1). This ﬁnding is not unexpected since NOTCH1-mutated
patients have a higher risk of progression. Fabbri et al.6 observed
that in 5 of 16 patients with Richter syndrome harboring NOTCH1
mutation, this alteration was not present in the CLL at diagnosis.
However, the mutational status of NOTCH1 over time in the
evolution of CLL before transformation has not been investigated.
Herein we report that, in a large series of 200 patients analyzed by
Sanger changes in NOTCH1 status were observed only in
3 patients, and more importantly, only 1 patient acquired the
mutation with no evidence of CLL progression. The disappearance
of NOTCH1 mutation after treatment has been previously reported
in one patient.21 The use of the more sensitive clonospeciﬁc PCR
demonstrated low levels of cells with NOTCH1 mutation in the
three cases. The identiﬁcation of these small subclones carrying
the mutation may reﬂect the complex ﬂuctuation of different
tumor subclones in the evolution of the disease. A recent study
using next-generation sequencing in three CLL patients22 has
highlighted the heterogeneous patterns of subclonal evolution of
the disease with many subclones present at very low frequencies
evolving over the years. The clinical impact of these subclones
carrying mutation at low levels will require further speciﬁc studies.
Moreover, no differences in NOTCH1 status were found when
comparing samples at CLL and at transformation with DLBCL.
These results suggest that acquisition of NOTCH1 mutation during
the evolution of the disease, although possible, is an uncommon
phenomenon. Further studies should clarify the relevance of the
modulation of clones carrying NOTCH1 mutations and whether
clones acquiring such mutation may emerge during the follow-up.
In our non-selected CLL series, we have conﬁrmed that NOTCH1
mutations are present in 11% of cases. This proportion is similar to
that found in a recent study of a similar large series of
patients.6,8,20 NOTCH1 mutations were associated with
Figure 2. Outcome from CR achievement. (a) PFS from CR
achievement according to NOTCH1-mutated (solid line) and
NOTCH1-unmutated (dashed line) (Po0  001). (b) Survival from
CR of NOTCH1-mutated CLL patients (solid line) and NOTCH1-
unmutated CLL patients (dashed line) (P¼ 0  003).
Figure 3. OS in CLL patients according to NOTCH1-mutated (solid
line) and NOTCH1-unmutated (dashed line) (Po0  001). The 95%
confidence interval for each group of patients is depicted.
Figure 4. Relative survival of CLL patients with NOTCH1-mutated
(solid line) and NOTCH1-unmutated (dashed line) CLL. The 95%
interval of confidence for each cohort is plotted.
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unmutated IGHV, and high expression of CD38 and ZAP-70, as well
as more frequently trisomy 12.8,19,23,24 In our study, we have
closely analyzed the impact of NOTCH1 mutations on the
requirement and response to treatment. Interestingly, patients
with NOTCH1 mutations required therapy more frequently
and earlier than patients with unmutated NOTCH1. Moreover,
patients with NOTCH1 mutation showed poorer response to
treatment, and shorter PFS and OS from CR achievement. Of note,
NOTCH1-mutated patients who achieved CR after front-line
therapy had poor outcome with 50% of them requiring further
therapy within 2 years. These patients, particularly if young and ﬁt,
would be candidates to intensive or investigational treatments.
However, more information is warranted from prospective clinical
trials to deﬁne the real impact of NOTCH1 mutations in CLL
patients.
Overall, patients with NOTCH1-mutated CLL had poor outcome
in terms of OS, which is in agreement with previous reports.4,8
Rossi et al.8 have recently observed that the impact of NOTCH1
mutations in OS is independent from IGHV. However, we could not
conﬁrm this ﬁnding in our study, in accordance with a previous
smaller series.20 The small group of patients with NOTCH1-
mutated IGHV-mutated in our series behaved as low-risk CLL, in
sharp contrast with the poor prognosis observed by Rossi et al.8
Transformation to DLBCL is an evolving event of CLL that occurs
in 0.5–1% of the patients per year. The development of DLBCL,
that confers an ominous prognosis to patients, has been
associated with unmutated and stereotyped immunoglobulin
genes, trisomy 12, del(11)(q22.3), mutations of TP53 and CDKN2A,
among others.25–28 Expanding our initial previous observation,4
the results of the current study demonstrate that NOTCH1
mutation is one of the most important predictors of DLBCL
development, with more than 30% of those patients having
developed DLBCL at 10 years of diagnosis. Rossi et al.8,29 have
reported a similar risk of transformation in NOTCH1-mutated
patients. In addition, we have observed that the higher risk of
DLBCL conferred by NOTCH1 mutation is independent from the
IGHV status. Acquisition of NOTCH1 mutation has been observed
in some patients at transformation to DLBCL.6 None of our
patients with sequential or simultaneous sample from non-
transformed and transformed tissue had differences in NOTCH1.
The presence of subclones with NOTCH1 mutation6 together with
technical reasons could account for the discrepancies.
The molecular mechanisms by which NOTCH1 mutation confers
higher risk of transformation and bad response to treatment are
unknown. In our previous study, we showed that the truncated
NOTCH1 protein encoded by mutated NOTCH1 is more stable,
accumulates in the cell and activates the downstream NOTCH1
signaling pathway.4 NOTCH1 activation induces several cellular
functions, including the activation of PI3K/Akt, MYC and NFkB
signaling pathways, that promote cell proliferation, survival
and angiogenesis, which may be important for the aggressive
behavior and frequent transformation of CLL cells.30–35
The relevance of NOTCH1 mutation in the CLL biology opens
the possibility of designing speciﬁc new therapeutic strategies for
these patients.36–38
In summary, we have shown that NOTCH1 mutation is a genetic
marker that deﬁnes a high-risk group of CLL patients characterized
by high risk of transformation and poor outcome. Although this
newly identiﬁed subgroup of patients only represents a 10% of
the whole CLL population, their increase risk in developing
DLCBL and dismal prognosis deserves speciﬁc investigation in
prospective clinical trials.
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